Grant's research team sought to develop a strategy to prevent the accumulation of MCL-1 in leukemia cells through a clinically effective treatment option. Building upon decades of their earlier ...

The clinical trial experience of combination therapy is limited and the optimal combinations and administration strategies have yet to be clarified.

Combination strategies with lenalidomide, bortezomib and dexamethasone seem to have a promising role in maintenance therapies for high-risk patients.

A combination of two widely available drugs could significantly reduce deaths from heart attacks, a study has found.  New ...

The combination not only killed the leukemia ... has now investigated a new strategy. STAT3 exists in two isoforms: STAT3α and STAT3β. While the α form promotes the expansion of cancer cells ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

The combination not only killed the leukemia cells ... Dr. Dagmar Stoiber-Sakaguchi, head of the Division of Pharmacology at the KL Krems, has now investigated a new strategy. TINY SHIFTS. BIG IMPACT.